DUBLIN, May 19, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the
"Personalized Medicine, Targeted Therapeutics and Companion
Diagnostic Market to 2021- Strategic Analysis of Industry Trends,
Technologies, Participants, and Environment" report to their
offering.
This is a comprehensive account of the market size,
segmentation, key players, SWOT analysis, influential technologies,
and business and economic environments. This report highlights a
number of significant pharmacos and gives details of their
operations, products, financials and business strategy.
The personalized medicine (global & USA) market is presented as follows:
By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY,
deCode /Amgen, CELERA, MYRIAD)
By Segment (Targeted therapeutics, Companion Diagnostics, Liquid
Biopsies)
By Sub-market (Companion diagnostic, targeted cancer therapeutic,
medical technology, pharmacogenomics, consumer genomics, molecular
diagnostics, liquid biopsy)
By Therapy (Cancer, Cardiovascular, Infectious Disease)
Key Opinion Leaders that contributed to interview questions
within the report include:
- Iain D. Miller, PhD, MBA, Founder
& CEO, Healthcare Strategies Group
- Stephen Finn, MBBS, PhD, Associate
Professor, Cancer Molecular Diagnostic Laboratory, Consultant
Histopathologist and Head of Histopathology, St James's Hospital
and Trinity College Dublin, Ireland
- Ronald Przygodzki, MD, Director,
Genomic Medicine Implementation at U.S. Department of Veterans
Affairs, Washington DC
- Elaine Kenny, PhD, Founder,
Elda Biotech, Dublin 2, Ireland
- Chad Clark, Co-President and Chief
Operating Officer, Precision for Medicine
- Tobias Guennel, PhD, Principal,
Biomarker and IVD Analytics, Precision for Medicine
- David Parker, PhD, Vice President,
Integrated Market Access, Precision for Medicine
- Deborah Phippard, PhD, Vice
President, Research, Precision for Medicine
- Judi Smith, MS, Vice President, In
Vitro Diagnostics Regulatory and Quality, Precision for
Medicine
A wealth of financial data & business strategy information
is provided including:
- Company financials, sales & revenue figures
- Business Model Strategies for Diagnostic, Pharmaceutical and
Biotechnology Companies
- Business Model Strategies for Providers. Provider Systems and
Academic Medical Centres
- Business Model Strategies for Payers & Governments
- Private and Public Funding and Personalized Medicine
Reimbursement
- Revisions to Current Payment Systems and intellectual
property
- How to Gain Market Penetration in the EU
- Cost-effectiveness and Business Value of Personalized
Medicine
- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis,
Oncotype Dx , KRAS Mutations)
- Comprehensive account of company product portfolios &
kits
SWOT, Economic & Regulatory Environment specifics
include:
- Key strengths, weaknesses and threats influencing leading player
position within the market
- Technologies driving the market (e.g., New-Generation Sequencing
Technologies, Ultra-High Throughput Sequencing)
- Top fastest growing market segments and emerging
opportunities
- Top pharmaceutical companies within the IPM by market share and
revenue
- Comprehensive product portfolios, R&D activity and pipeline
therapeutics
- M&A activity and future strategies of top personalized
medicine pharmacos
- Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy)
- CE-marked Personalized Medicine/Diagnostic Tests
- FDA Advances in Personalized Medicine Regulation
What you will gain:
- An in-depth understanding of the global personalized medicine
market and it's environment
- Current market facts, figures and product lines of key players in
the industry
- Emerging trends in key markets such as the US, UK, Germany and France
- Knowledge of how the personalized medicine market will integrate
into the global healthcare market
- Technical insights into new generation sequencing technologies
and ultra-high throughput sequencing
- Updates on bioinformatics, high throughput systems, genetic
analysis kits, companion diagnostics and future technologies
- FDA approved pharmacogenetic tests and recognized biomarkers
- Information on key government and regulatory policies
- Strategies on how to adapt and restructure current business
models to this industry
This report tackles key concerns to the personalized medicine
market such as:
- Lack of regulatory policy and legislation in the US and
Europe
- Reimbursement schemes and payers concerns
- Transition of investigational diagnostic assays and therapeutics
to clinical practice
- Direct to consumer (DTC) test kits and implications for the
public
This report will tell you if the companies mentioned
are:
- Strong, competitive players
- Pooling their resources for specific growth and therapeutic
areas
- Investing strategically in R&D
- Have a history of strategic M&A activity
Key Topics Covered:
1.0 Executive Summary
2.0 Introduction and Background
3.0 Personalized Medicine Targeted Therapeutics and Associated
Companion Diagnostics
4.0 Personalized Medicine and Integration into the Healthcare
System
5.0 Private and Public Funding and Personalized Medicine
Reimbursement
6.0 European Personalized Medicine Market - Payments and
Investment
7.0 Personalized Medicine -Business Model Analysis
8.0 Personalized Medicine Main Industry Players
9.0 Personalized Medicine Market Analysis
10.0 Strengths and Advantages of Personalized Medicine
11.0 Restraints of the Personalized Medicine Market
12.0 Personalized Medicine and Regulatory Policies
13.0 Final Summary and Future Perspectives
14.0 Interviews with Key Opinion Leaders
Companies Mentioned
- 23andMe
- Abbott Laboratories
- Agendia
- Alere
- Amgen
- Astex Pharmaceuticals
- AstraZeneca
- Atossa Genetics
- Becton Dickenson
- bioMerieux
- BristolMyersSquibb
- ELDA BioTech
- Eisai
- Eli Lilly
- Foundation Medicine
- Genelex
- GlaxoSmithKline
- HalioDx
- Johnson & Johnson
- LabCorp
- Life Technologies
- MDxHealth
- Merck
- MolecularMD Corporation
- Novartis MDx
- Orion Genomics
- Oxford BioTherapeutics
- Pfizer
- Qiagen
- Roche Molecular Diagnostics
- Sanofi
- SensiGen
- Siemens Healthcare Diagnostics
- Ventana (Roche)
- Vertex Pharmaceuticals
For more information about this report visit
http://www.researchandmarkets.com/research/wk98zk/personalized
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716